Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dendritic Cell Vaccines in Stage III/IV Melanoma
NCT00085397Phase 2Unknown
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Mar 2004
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of autologous dendritic cell-tumor fusion vaccine, Intus in melanoma, sponsored by Dana-Farber Cancer Institute. Status: unknown.
02
Drugs
autologous dendritic cell-tumor fusion vaccineIntus
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00085397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00085397.